1-5 of 5
Janet Anderl
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Immunoproteasome Inhibition in Preclinical Studies of Hemophagocytic Lymphohistiocytosis

Camille Keenan, Sabrin Albeituni, Alexa Stroh, Heather Tillman, Janet Anderl, Christopher J. Kirk, Kim E. Nichols
Journal: Blood
Blood (2022) 140 (Supplement 1): 34–35.
https://doi.org/10.1182/blood-2022-166779
Published: 2022
Journal Articles

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Clinical Trials & Observations
James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal, Jesus G. Berdeja
Journal: Blood
Blood (2016) 127 (26): 3360–3368.
https://doi.org/10.1182/blood-2015-11-683854
Published: 2016
Includes: Supplemental data
Journal Articles

Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)

James Berenson, MD, Alan Cartmell, Roger Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph V. Boccia, MD, Morton Coleman, Robert A. Moss, MD, Robert M. Rifkin, Marco Schupp, Sandra Dixon, Ying Ou, Janet Anderl, Jesus G. Berdeja, MD
Journal: Blood
Blood (2015) 126 (23): 373.
https://doi.org/10.1182/blood.V126.23.373.373
Published: 2015
Journal Articles

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Denise Niewerth, MSc, Johan van Meerloo, MSc, Yehuda Assaraf, PhD, Gerrit Jansen, PhD, Tessa C Hendrickx, BSc, Christopher J. Kirk, Ph.D, Janet Anderl, MS, Sonja Zweegman, MD PhD, Jacqueline Cloos, PhD, Gertjan Kaspers, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3841.
https://doi.org/10.1182/blood.V122.21.3841.3841
Published: 2013
Journal Articles

Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Irene M. Ghobrial, MD, Jonathan L. Kaufman, MD, David S. Siegel, MD, PhD, Ravi Vij, MD, Ashraf Badros, MD, Linda Neuman, MD, Hansen Wong, PhD, Janet Anderl, MS, Michael Savona, MD
Journal: Blood
Blood (2013) 122 (21): 3184.
https://doi.org/10.1182/blood.V122.21.3184.3184
Published: 2013